Radiofrequency Catheter Ablation for Chronic Atrial Fibrillation
This study has been completed.
Sponsor:
University of Michigan, Section of Electrophysiology (Arrhythmia Research)
Collaborator:
San Raffaele University Hospital, Italy
Information provided by:
University of Michigan, Section of Electrophysiology (Arrhythmia Research)
ClinicalTrials.gov Identifier:
NCT00272636
First received: January 3, 2006
Last updated: NA
Last verified: January 2006
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the long-term efficacy of radiofrequency catheter ablation in patients with chronic atrial fibrillation.
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation |
Procedure: Radiofrequency catheter ablation Drug: Amiodarone and cardioversion |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Comparison of Radiofrequency Catheter Ablation Vs. Antiarrhythmic Therapy With Amiodarone for Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation |
Resource links provided by NLM:
Genetics Home Reference related topics:
familial atrial fibrillation
MedlinePlus related topics:
Atrial Fibrillation
U.S. FDA Resources
Further study details as provided by University of Michigan, Section of Electrophysiology (Arrhythmia Research):
Primary Outcome Measures:
- Freedom from atrial fibrillation and atrial flutter in the absence of antiarrhythmic drug therapy at 1 year.
Secondary Outcome Measures:
- incidence of complications
- changes in left atrial diameter
- changes in left ventricular ejection fraction
- changes in symptom severity
| Estimated Enrollment: | 140 |
| Study Start Date: | November 2002 |
| Estimated Study Completion Date: | February 2005 |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Chronic atrial fibrillation
Exclusion Criteria:
- Left atrial diameter >55 mm
- Left ventricular ejection fraction <0.30
- Contraindication to amiodarone therapy or anticoagulation with warfarin
- Presence of a mechanical prosthetic valve
- History of a cerebrovascular accident
- Presence of left atrial thrombus on TEE
- Prior attempt at catheter or surgical ablation for atrial fibrillation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00272636
Locations
| United States, Michigan | |
| University of Michigan Health System | |
| Ann Arbor, Michigan, United States, 48109 | |
| Italy | |
| San Raffaele Hospital | |
| Milan, Italy | |
Sponsors and Collaborators
University of Michigan, Section of Electrophysiology (Arrhythmia Research)
San Raffaele University Hospital, Italy
Investigators
| Principal Investigator: | Hakan Oral, MD | University of Michigan |
| Study Chair: | Fred Morady, MD | University of Michigan |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00272636 History of Changes |
| Other Study ID Numbers: | 2002-0480 |
| Study First Received: | January 3, 2006 |
| Last Updated: | January 3, 2006 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Michigan, Section of Electrophysiology (Arrhythmia Research):
|
atrial fibrillation catheter ablation amiodarone cardioversion |
Additional relevant MeSH terms:
|
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Amiodarone Anti-Arrhythmia Agents |
Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Vasodilator Agents |
ClinicalTrials.gov processed this record on May 19, 2013